Jeffrey W. Albers insider trades

Open-market stock purchases and sales by Jeffrey W. Albers, Director at Spyre Therapeutics, Inc, from SEC Form 4 filings since Nov 2, 2015.

Recent trades

DateStockTradeValue
Aug 7, 2026SYRE Spyre Therapeutics, IncSold$522K
Aug 7, 2026SYRE Spyre Therapeutics, IncSold$835K
Aug 7, 2026SYRE Spyre Therapeutics, IncSold$1M
Aug 7, 2026SYRE Spyre Therapeutics, IncBought (not open market)—
Jun 24, 2026KYMR Kymera Therapeutics, IncBought (not open market)—
May 27, 2026SYRE Spyre Therapeutics, IncBought (not open market)—
Dec 8, 2025KYMR Kymera Therapeutics, IncSold$245K
Dec 8, 2025KYMR Kymera Therapeutics, IncSold$203K
Dec 8, 2025KYMR Kymera Therapeutics, IncBought (not open market)—

Companies traded

  • SYRE Spyre Therapeutics, Inc: 5 sales, last Aug 7, 2026
  • KYMR Kymera Therapeutics, Inc: 8 sales, last Jun 24, 2026
  • BPMC Blueprint Medicines Corp: 147 sales, last Jul 17, 2025
  • AGLE Spyre Therapeutics, Inc: other filings, last Nov 22, 2023
  • MGTA Magenta Therapeutics, Inc: other filings, last Jun 28, 2022

Get free alerts when Jeffrey W. Albers files a new trade →